AMA recognizes the following companies as the key players who are driving Oral Proteins and Peptides market, some of them are Allergan (Ireland), AstraZeneca (United Kingdom), Biocon (India), Generex Biotechnology (United States), Novo Nordisk (United States), Synergy Pharmaceuticals (United Arab Emirates), Tarsa Therapeutics (United States), Sanofi (France), Hoffmann-La Roche (Switzerland) and Synthetic Biologics (United States).

An analyst from AdvanceMarketAnalytics team said: “One of the key factors which is trending the market is “Improvement in healthcare settings”. Considering the revolutionary changes occurring in this market, there is a growing demand from the use of Oral Proteins and Peptides such as Linaclotide, Plecanatide, Calcitonin, Insulin and Octreotide.

According to the report, some of the important driving forces behind the market growth are “Increase in prevalence of chronic diseases, ”. The primary concern of any business is the reduction of the overall operating cost. The increased need for operating efficiency and meeting regulatory demands at the same time have become major challenges for the original Players, additional restraints impacting market are “Hgh costs associated with oral peptides and proteins” which is continuously seeking attention of Industry Experts and Decision makers.

The study was conducted using primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market study and vendor landscape in addition to a SWOT analysis of the key Players.

Available Customization: List of players that can be included in the study on immediate basis are Hovione and Novartis.